mRNA Structural Characterization Service
The clinical success of messenger RNA (mRNA) therapeutics is fundamentally dependent on the molecule's structural integrity, purity, and the precision of its critical features. CD BioGlyco offers an industry-leading mRNA structural characterization service, providing researchers and therapeutic developers with the high-resolution data necessary to ensure product safety and biological efficacy. As mRNA molecules are inherently large and complex, traditional analytical methods often fall short of identifying subtle variations in sequence, capping efficiency, or poly(A) tail heterogeneity. Our platform integrates advanced mass spectrometry, capillary electrophoresis, and biophysical profiling to deliver a multi-dimensional map of your mRNA construct. By partnering with us, you gain access to a rigorous analytical framework designed to meet stringent regulatory requirements and accelerate the transition from discovery to the clinic.
Our analytical suite leverages the latest advancements in molecular characterization to provide a holistic view of mRNA and its delivery vehicle.
Utilizing partial RNase T1 digestion and magnetic particle separation to achieve direct sequence mapping and identification of site-specific modifications or impurities.
A revolutionary technique that measures the molecular weight of individual mRNA molecules in solution, providing unprecedented insights into mass distribution and the presence of aggregates or degradants.
High-sensitivity fragment analysis is used to assess mRNA integrity, length distribution, and the presence of residual double-stranded RNA (dsRNA) species.
Precision measurement of nanoparticle size, surface charge, and lipid-cargo interactions using automated Dynamic Light Scattering (DLS) and Zeta potential analysis.
We offer an expansive suite of characterization capabilities tailored to the diverse needs of the biotechnology sector. We specialize in the identification of secondary structure motifs that may interfere with ribosome loading or trigger unwanted innate immune responses. Beyond the RNA molecule itself, our service extends to the structural interrogation of the delivery system. We analyze the "cargo-carrier" relationship, determining how mRNA folding influences its packaging within LNPs and its subsequent release kinetics. This includes measuring the polydispersity of the encapsulated species and the impact of intrinsic lipid components on the overall structural stability of the drug product. Whether you are in the early discovery phase, optimizing a codon-optimized sequence, or in late-stage development requiring rigorous batch-to-batch comparability studies, our service scope is designed to provide the granularity needed to move your program forward with confidence.
Quantifying the percentage of full-length transcripts versus degraded fragments using automated electrophoresis.
Detection and quantification of process-related impurities and non-target RNA species.
Precise determination of nucleotide count to verify consistency with the theoretical construct design.
High-sensitivity qPCR-based detection of residual template DNA from the IVT process.
Quantification of residual RNA polymerases or other processing enzymes using ELISA or LC-MS.
Identification of cap structure types (e.g., Cap 0, Cap 1) and validation of site-specific methylation.
Direct sequence mapping via LC-MS/MS to ensure 100% fidelity and identify potential transcriptional errors.
Assessment of translational efficiency in cell-free systems or reporter-based cell lines.
Determination of the ratio between capped and uncapped mRNA populations for regulatory compliance.
High-resolution profiling of tail length distribution is critical for predicting in vivo half-life.
Specialized assays for detecting trace amounts of genomic or plasmid DNA following DNase treatment.
Immunological or chromatographic detection of immunogenic dsRNA byproducts.
Measurement of the hydrodynamic radius of the mRNA molecule or its encapsulated nanoparticle form.
Assessment of the uniformity of mRNA or mRNA-LNP populations to ensure batch-to-batch consistency.
Measuring the surface charge of delivery vehicles to predict stability and cellular uptake efficiency.
Quantifying the ratio and purity of individual lipid components within LNP formulations.
Our technical team performs a thorough review of your mRNA sequence, production methodology, and intended application. Based on this evaluation, we design a customized analytical characterization panel that aligns with your specific regulatory, developmental, or quality control milestones, ensuring that all critical attributes are assessed appropriately throughout the product lifecycle.
mRNA samples are first stabilized under controlled conditions to preserve integrity. Where required, they undergo site-specific enzymatic digestion, using nucleases such as RNase T1 or RNase H, to generate defined fragments. This step enables high-resolution mapping of structural features, modifications, and sequence regions of interest for downstream analysis.
Processed samples are analyzed using our integrated technology platform. This includes high-resolution mass spectrometry for precise sequence confirmation and modification mapping, as well as mass photometry for determining intact molecular mass, assessing aggregation, and evaluating sample polydispersity in a label-free manner.
We perform targeted quantitative assays to evaluate key quality attributes. These include measurement of 5' cap efficiency (Cap 0 vs. Cap 1), poly(A) tail length distribution via sequencing or fragment analysis, and detection of residual process-related impurities such as DNA templates, host cell proteins, and truncated RNA species.
Data from multiple analytical streams are consolidated using proprietary bioinformatic and chemometric algorithms. This integration enables the construction of a comprehensive structural profile, linking biochemical characteristics, such as modification patterns and impurity levels, to predicted functional outcomes, including mRNA stability, translational efficiency, and immunogenicity potential.
Clients receive a complete analytical dossier that consolidates all findings. The report includes raw and processed data (e.g., chromatograms, mass spectra, electrophoretic traces), detailed interpretation of results against predefined specifications, and actionable insights to support process optimization, regulatory submissions, or further development decisions.
Journal: Analytical Chemistry
DOI: 10.1021/acs.analchem.2c00765
IF: 6.7
Published: 2023
Results: In this study, the authors present an automated, high-throughput workflow for the rapid characterization and sequence mapping of large RNA and mRNA therapeutics using mass spectrometry, addressing the critical need for robust analytical methods in the burgeoning field of RNA-based therapies. Their innovative approach utilizes partial RNase T1 digestions with enzymes immobilized on magnetic particles, enabling controlled fragmentation that generates longer oligoribonucleotides with missed cleavages, which are uniquely mappable to the RNA sequence. These digests are analyzed via high-resolution LC-MS/MS, and an automated software tool facilitates oligoribonucleotide identification and annotation based on accurate mass and MS/MS fragmentation spectra. This method achieves remarkable sequence coverage exceeding 80% for various large RNAs, including mRNA encoding the SARS-CoV-2 spike protein, in a single analysis completed within 90 minutes. The technique provides high specificity, with minimal matches to random control sequences, and is successfully applied to both unmodified and chemically modified mRNAs, demonstrating its utility for identity testing, sequence validation, and impurity analysis in therapeutic development.
Prophylactic Vaccine Development
Structural characterization is essential for ensuring the consistency and potency of mRNA vaccines against infectious diseases, where capping efficiency directly impacts the magnitude of the immune response.
Oncology Immunotherapy
Precise sequence mapping ensures that neoantigen-encoding mRNA constructs are synthesized without errors, which is critical for the safety and efficacy of personalized cancer treatment strategies.
Ocular and Localized Delivery
For therapies delivered to immune-privileged sites, characterization of purity and surface charge is vital to avoid inflammation and ensure effective cellular internalization within target tissues.
RNA-Based Adjuvants
Structural profiling of non-coding RNA molecules used as molecular patterns helps in optimizing their interaction with Toll-like receptors and other innate immune sensors for enhanced vaccine efficacy.
Unrivaled Analytical Resolution
We utilize mass spectrometry-based sequence mapping that can distinguish single-nucleotide variations and modifications, providing a level of detail far beyond standard sequencing or gel-based methods.
Comprehensive Impurity Detection
We employ a multi-orthogonal approach to detect trace impurities like dsRNA and residual DNA, which are known to trigger adverse immune responses, thereby improving the safety profile of your therapeutic.
Advanced Feature Mapping
Our proprietary enzymatic digestion strategies allow for the simultaneous analysis of the 5' cap and 3' poly(A) tail, providing a complete picture of the molecule's functional architecture in a single study.
Accelerated Development Timelines
By integrating automated characterization workflows, we reduce the time from sample submission to data delivery, allowing your team to make faster, data-driven decisions during the optimization of IVT processes.
CD BioGlyco provided a level of detail in our mRNA sequence mapping that we simply couldn't find elsewhere. Their MS-based approach identified a recurring truncation issue that saved us months of troubleshooting.
— By Dr. A.G. Thompson, Director of Analytical Sciences
Working with CD BioGlyco has been a seamless experience. Their mass photometry data gave us a completely new perspective on our mRNA aggregation profiles, which led to a much more stable final formulation.
— By Technical Lead, Gene Therapy Group
The characterization of our LNP-encapsulated mRNA was comprehensive and insightful. CD BioGlyco doesn't just provide raw data; they provide real scientific interpretation that adds value to our research.
— By Dr. M.S. Rodriguez, Principal Investigator, Molecular Biology
Oral Solid Dose Formulation Development Service
Expert optimization of solid dosage forms for a wide range of therapeutic applications.
Rectal Dosage Formulation Development Service
Specialized formulation strategies for localized or systemic delivery via rectal administration.
Non-sterile Liquid Dose Formulation Development Service
Comprehensive development of oral liquids, suspensions, and topical solutions.
Sterile Liquid Formulation Development Service
Precision development of injectable and ophthalmic liquid formulations under strict aseptic standards.
Lyophilized Drug Formulation Development Service
Advanced freeze-drying cycle optimization to ensure the long-term stability of sensitive biologics.
CD BioGlyco is committed to providing the highest caliber of analytical support for the next generation of genetic medicines. Our mRNA structural characterization service empowers you with the deep molecular insights needed to ensure your therapeutic is safe, potent, and ready for the challenges of clinical development. With a focus on technical excellence and regulatory alignment, we are the partner of choice for leading biotechnology companies and academic institutions worldwide, contact us!
Reference
